Catalyst Pharma Files Preliminary Proxy for $4.1B Acquisition by Angelini Pharma
Summary
Catalyst Pharmaceuticals has filed a preliminary proxy statement for its special shareholder meeting to vote on the $4.1 billion all-cash acquisition by Angelini Pharma at $31.50 per share.
Key Events
-
Merger Agreement Details
Catalyst Pharmaceuticals is seeking shareholder approval for its acquisition by Angelini Pharma for $31.50 per share in cash, based on the merger agreement dated May 6, 2026.
-
Transaction Value & Premium
The deal is valued at approximately $4.1 billion, representing a 21% premium to Catalyst's unaffected closing share price on April 22, 2026.
-
Board Recommendation & Fairness Opinion
The Board of Directors unanimously recommends shareholders vote FOR the merger, supported by a fairness opinion from J.P. Morgan Securities LLC.
-
Executive Interests & Voting Agreements
Executive officers and directors have interests in the merger, including accelerated equity vesting, and have signed voting agreements to support the transaction.
Analysis
This preliminary proxy statement details the proposed acquisition of Catalyst Pharmaceuticals by Angelini Pharma for $31.50 per share in cash. The filing provides comprehensive information for shareholders to vote on the merger, including the board's unanimous recommendation, a fairness opinion from J.P. Morgan, and details on executive compensation related to the transaction. The deal, valued at approximately $4.1 billion, represents a significant premium to Catalyst's unaffected share price and is a critical step towards the transaction's completion, expected in Q3 2026.
At the time of this filing, CPRX was trading at $31.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.05 to $32.56. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.